n n n ‘.concat(e.i18n.t(“search.voice.recognition_retry”),’n
In recent years, there has been strong growth in the expansion of the CMO and CDMO industries. The pharmaceutical and biotechnology industries, seeing the benefits of cost-effectiveness, adaptability and access to expertise, are turning to outsourcing their production and progression services.
NEWARK, Del. , Dec. 06, 2023 (GLOBE NEWSWIRE) — Brazil’s CMO/CDMO enterprise sector is expected to grow to $697. 93 million by 2023. It is expected to grow at a CAGR of 2. 7% during the forecast era (2023). to 2023). 2033). The company is expected to reach a valuation of approximately $907. 67 million through 2033.
The contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) space in Brazil is a dynamic and rapidly evolving sector in the pharmaceutical and biotechnology businesses. Brazil, one of the leading pharmaceutical ecosystems in Latin America, offers significant opportunities and challenges for CMOs and CDMOs.
Request a pattern from this report: https://www. futuremarketinsights. com/reports/pattern/rep-gb-18061
The pharmaceutical sector in Brazil has been expanding rapidly in recent years, driven by factors such as an aging population, increased healthcare access, and a growing middle class. This growth has translated into a rising demand for pharmaceutical products and manufacturing services, making Brazil an attractive destination for CMOs and CDMOs.
The Brazilian Health Regulatory Agency (ANVISA) enforces strict regulatory standards for pharmaceutical manufacturing. CMOs and CDMOs that can navigate and assist clients in meeting these regulatory requirements gain a competitive advantage in the business.
To operate effectively in Brazil, pharmaceutical companies are often required to have a local manufacturing presence. This has led to collaborations and partnerships with local CMOs and CDMOs, both domestic and international.
Brazil’s pharmaceutical landscape is increasingly focusing on biotechnology, including the development of biologics, biosimilars, and advanced therapies. CMOs and CDMOs with expertise in biomanufacturing are well-positioned to cater to this growing segment.
Key takeaways from the CMO/CDMO business in Brazil:
By service, the independent segment is expected to have a share of 46. 2% and achieve a CAGR of 3. 4% through 2033.
By product, API substrates are expected to show a lucrative CAGR of 1. 9% from 2023 to 2033.
By expression system, the mammal segment is most likely to grow at a CAGR of 2. 7% during the estimated period.
By company size, the mid-sized companies segment is anticipated to record a CAGR of 2.3% in the evaluation period.
Based on the scale of operation, the announcement is expected to register a CAGR of 2. 9% from 2023 to 2033.
Southeast Brazil will be the leading region with a price share of 68. 6% at the end of the forecast period.
“With the increasing complexity of drug development, specialization in areas of rapid healing, and high-quality manufacturing, the Brazilian CMO/CDMO business is expected to grow during the forecast period,” said Sabyasachi Ghosh, associate vice president at Future Market Insights (FMI).
Brazil CMO/CDMO Business Report Scope:
Attribute
Details
Brazil CMO-CDMO (2022)
$679. 10 million
Brazil CMO-CDMO Projected Revenue (2033)
$907. 67 million
Value-based CAGR (2023 to 2033)
2,7%
Forecast Period
2023 to 2033
Historical Data Available for
2018 to 2022
Business Analysis
Value (millions of U. S. dollars)
Key Regions Covered
Northern Brazil, Northeast Brazil, Central-West Brazil, Southeastern Brazil and Southern Brazil
Key Segments Covered
Services
Product
Expression System
Company Size
Scale of Operations
Region
Key Profiled Companies
Lonza AG
Uniting Pharmaceuticals
Catalent Inc.
Fagron
Eurofarma
Pfizer CentreOne
Patheon NV (Thermo Fisher Scientific, Inc. )
NUVISAN
Social CDMO
Bio-Manguinhos
Biotimize
Pierre Fabre Group
Ajinomoto Co. , Inc.
Act now to explore in-depth market analysis – get an exclusive reduction for industry trends now: https://www. futuremarketplaceinsights. com/checkout/18061
Competitive Landscape:
Expansion and acquisition between leading corporations or brands is the key strategy for brands in the ecosystem, such as Catalent and Fragon, among others. Its objective is to strengthen its presence in the sector and compete with other corporations in the forecast period. Below are some examples of the latest developments:
In February 2022, Pharma Nobis, LLC finalized the acquisition of Fagron’s contract production and production facilities.
In August 2022, Catalent made an announcement regarding its acquisition of Metrics Contract Services. Metrics Contract Services is a specialized Contract Development and Manufacturing Organization (CDMO) known for its 333,000-square-foot facility located in Greenville.
Prospects for the Brazilian CMO/CDMO by category:
For services:
Self-employed services
Cell Line Development
Development and Bio Manufacturing
Analytical Services
Finishing the Filling
packing
Clinical Supply Services
Integrated development
Generation Scaling & Transfer
Technology & Innovation
Quality Control & Quality Assurance
Regulatory Assistance
By Product:
API Substrate
Large Molecule
Monoclonal antibodies
Antibody fragments
Recombinant Therapeutic Proteins
Viral Vectors
Cell & Gene Therapy
Vaccine
Peptides
Antibody Drug Conjugates (ADCs)
small molecule
By Expression System:
Mammalian
Microbial
bacteria
Yeast
By corporate size:
litle
Medium size
Big
Very large
By Scale of Operation:
Preclinical
Clinical
The I
Phase II
Phase III
Commercial
Author by:
Sabyasachi Ghosh (Associate Vice President, Future Market Insights, Inc. ) has more than 12 years of experience in the pharmaceutical, medical device, and healthcare industries. His inquisitive and analytical nature helped shape his career as a researcher.
Identifying the key and demanding situations customers face and designing physically powerful responses on assumptions to give them strategic decision-making roles is a natural fit for him. His core expertise lies in areas such as market access and expansion strategy, feasibility studies, competitive intelligence, and strategic transformation. .
Sabyasachi holds a bachelor’s degree in microbiology, has authored publications, and has been cited in journals such as The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore similar ongoing FMI activities in the area of Healthcare Market Insights:
CMO/CDMO Market Size: The global CMO/CDMO market is estimated to be worth $22. 5 billion by 2023. The market is expected to reach $39. 4 billion through 2033, growing at a CAGR of 5. 7% from 2023 to 2033.
Small Molecule CMO/CDMO Market Share: According to research by Future Market Insights, over the projected period, the global small molecule CMO/CDMO market is expected to grow at a CAGR of 5. 2%. The market price is expected to rise from the U. S. to the U. S. U. S. $74,998. 1 million in 2024 to $124,532. 4 million through 2034.
Expectorant Drugs Market Demand: The expectorant drugs market is expected to generate $17,648. 2 million in 2024. The profits of the expectorant drugs market are expected to reach $38,455. 4 million through 2034. A CAGR of 4. 3% is expected for expectorant drugs. Marketplaceplaceplace the forecast period.
ECG Devices Market Growth: The duration of the global ECG devices market is expected to exceed a valuation of 15,725. 60 million U. S. dollars by 2034. According to the analysis, the ECG devices market is most likely to grow at a CAGR of 7. 2% until 2034, with an existing valuation. US$ 7,833. 5 million in 2024.
Digital Scale Market Trends: The global digital scale market is expected to rise at a CAGR of 4.5% through 2034. The market value is projected to increase from US$ 564.6 million in 2024 to US$ 877.1 million by 2034.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award winner, and member of the New York Chamber of Commerce) offers an in-depth look at the driving points driving demands in the marketplace. FMI is the world’s leading provider of market services. Intelligence, consulting, advisory and occasion facilities for the packaging, food and beverage, customer technology, healthcare, commercial and chemical markets. With an extensive team of more than 5000 analysts worldwide, FMI provides global, regional and local expertise in industry spaces and trends. in more than 110 countries.
Contact us:
Nandini Singh Sawlani
Future Market Insights Inc. Christiana Corporate, Two Hundred Continental Drive, Suite 401, Newark, Delaware – 19713, USAU. S. AT: 1-845-579-5705 For sales inquiries: sales@futuremarketinsights. com Website: https://www. futuremarketinsights. enLinkedIn| Twitter| Blogs | YouTube